Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder
Autore:
Grcevich, S;
Indirizzi:
Univ Hosp Cleveland, Div Child & Adolescent Psychiat, Cleveland, OH 44106 USA Univ Hosp Cleveland Cleveland OH USA 44106 chiat, Cleveland, OH 44106 USA
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 11, volume: 10, anno: 2001,
pagine: 2003 - 2011
SICI:
1354-3784(200111)10:11<2003:SALPPF>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
DEFICIT/HYPERACTIVITY-DISORDER; METHYLPHENIDATE; CHILDREN; ADDERALL(R);
Keywords:
adderall; amphetamines; attention-deficit hyperactivity disorder; psychostimulants;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Grcevich, S Univ Hosp Cleveland, Div Child & Adolescent Psychiat, Cleveland, OH 44106 USA Univ Hosp Cleveland Cleveland OH USA 44106 land, OH 44106 USA
Citazione:
S. Grcevich, "SLI381: a long-acting psychostimulant preparation for the treatment of attention-deficit hyperactivity disorder", EXPERT OP I, 10(11), 2001, pp. 2003-2011

Abstract

SL1381 (Adderall-XR (R)) is a longer-acting form of Adderall (R), a compound of mixed amphetamine salts that is now the most frequently prescribed brand of psychostimulant medication for attention-deficit hyperactivity disorder (ADHD) in the US [1]. It has been demonstrated to be a safe and effective treatment for ADHD in school-age children. To date, the efficacy of SL1381 has been evaluated in controlled studies of over 500 patients. The therapeutic effects of SL1381 on the core symptoms of ADHD, as well as the duration of action of the formulation, have been demonstrated to persist for 12 h, with both greater efficacy and duration of effects seen at higher doses. Both behavioural and cognitive performance measures are improved throughout the school day and into post-school activities. The incidence of common stimulant-emergent side effects with SL1381 was no different than that seen with the existing Adderall preparation. Additionally, the frequency with which most stimulant-related side effects were experienced did not demonstrate a consistent dose-related incidence, with the exception of anorexia. SL1381 received a letter of approvability in August 2001 and will probably be approved in the immediate future by the US FDA. This formulation represents a valuable addition to the available pharmacotherapeutic options for ADHD by providing an amphetamine-based stimulant offering the advantages of once-daily dosing accompanied by the clinical benefits of ADHD symptom control associated with the now widely used Adderall preparation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/01/20 alle ore 16:04:54